Serostim
Traumatic Brain Injury
Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Anhui Provincial Hospital
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07481656CT.gov Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) | — | Not Yet Recruiting | — | — | — |
NCT04867317CT.gov Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | — | Recruiting | — | — | — |
NCT05660356CT.gov Growth Hormone Deficiency in Mild Traumatic Brain Injury | — | Unknown | — | — | — |
NCT04121780CT.gov Growth Hormone Replacement Therapy for Retried Professional Football Players | — | Recruiting | — | — | — |
NCT03554265CT.gov Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy | — | Completed | — | — | — |
NCT02114775CT.gov Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI) | — | Completed | — | — | — |
NCT01699308CT.gov Growth Hormone and Brain Functioning After Traumatic Brain Injury | — | Completed | — | — | — |
NCT00766038CT.gov Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury. | — | Completed | — | — | — |
NCT00957671CT.gov Anterior Pituitary Hormone Replacement in Traumatic Brain Injury | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Traumatic Brain Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Serostim (this asset) | Anhui Provincial Hospital | Approved | BB · 69 |
| Melatonin | Children's National Research Institute | P4 | BBB |
| Valproic Acid | Northwestern University | P4 | BBB |
| Apsolol | Tanta University | P4 | BBB |
| Nepenthe | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Amantadine | SHINKEI Therapeutics, Inc | P4 | BB |
| Dexmedetomidine | Universitas Jenderal Soedirman | P4 | BB |
| Lacto-Flavin | POLYSAN Scientific & Technological Pharmaceutical Company | P3 | BB |
| Dextromethorphan | Avanir Pharmaceuticals | P4 | BB |
+42 more in the Traumatic Brain Injury cohort
Other indications for Serostim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Isolated Congenital Growth Hormone Deficiency | — | P4 | BBB · 77 |
| Prader-Willi Syndrome | — | P4 | BBB · 77 |
| Lipodystrophy | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Serostim in Traumatic Brain Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/somatropin-recombinant-traumatic-brain-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →